Results of General Meeting and Total Voting Rights

RNS Number : 2840K
Medaphor Group PLC
12 December 2018
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

12 December 2018

 

 

MedaPhor Group plc

 

("MedaPhor" or the "Group" or the "Company")

 

Results of General Meeting

and

Total Voting Rights

 

 

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders. Accordingly, the Company has raised £5.08 million in the Placing and Open Offer and has issued and allotted 59,750,331 Placing and Open Offer Shares, conditional only on Admission becoming effective. Admission of the Placing and Open Offer Shares is expected at 8.00 a.m. on 13 December 2018.

 

Following Admission, the Company's issued ordinary share capital will comprise 156,627,749 Ordinary Shares, of which none are held in treasury. The above figure of 156,627,749 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 26 November 2018.

Enquiries:

MedaPhor Group plc 

www.medaphor.com

Stuart Gall, CEO 
Wilson Jennings, CFO

Tel: +44 (0)29 2075 6534 



Cenkos Securities - Nominated Advisor and broker

Tel:  +44 (0)20 7397 8900 

Mark Connelly / Cameron MacRitchie (Corporate Finance)


Michael Johnson / Julian Morse (Sales) 




Walbrook PR 

Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGGPPPUPRGWP
UK 100

Latest directors dealings